GZMO Message Board - Msg: 14506587

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (297)	10/3/2000 9:34:23 PM
From: Spekulatius	Read Replies (1) of 438

It seems that GZMO is getting a nice and broad cancer vaccine pipeline moving. GP100 melanoma PhI/II Dendritic cell breast cancer PhI/II Dendritic cell fusion kidney cancer PhI/II ESO vaccine -preclinical It seems that they are taking the shotgun approach and try different technologies and cancer indications to diversify the risk. They have got SAGE as a fairly powerful discovery tool. The technology breadth of GZMO is unique for a company with a market cap of 200M$ only. And I am not even counting the preclinical stuff like the aaATIII and the outlicensed P53 / MD2/P53. If this array of different approaches and technologies includes only one big winner,we will be richly rewarded.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next